Retatrutide Reference Overview

Retatrutide Reference Overview

Compound Reference Overview

Field Value
Name Retatrutide
Reference Code GLP-3RT
Category Triple GLP-1 / GIP / Glucagon Receptor Agonist
Example Strengths 1 mg, 2 mg, 4 mg, 8 mg, 12 mg (clinical trial doses; investigational)
Reference Range 1 mg – 12 mg once weekly (evaluated in Phase 2 and Phase 3 clinical trials)
Frequency Once weekly (clinical trial reference)
Key Safety Warning Investigational Status: Retatrutide is not FDA approved and remains under clinical investigation. GLP-1 class boxed warning: Risk of thyroid C-cell tumors observed in rodent models. Contraindicated in individuals with personal or family history of medullary thyroid carcinoma (MTC) or MEN2.

Mechanism of Action (Educational)

Retatrutide is a triple agonist targeting the GLP-1 receptor, GIP receptor, and glucagon receptor. Simultaneous activation of GLP-1 and GIP pathways enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central hypothalamic mechanisms.

In addition, glucagon receptor agonism is believed to increase energy expenditure through hepatic lipid metabolism and thermogenic pathways. The combined incretin and glucagon receptor activation differentiates retatrutide from dual-agonist therapies and may contribute to the magnitude of weight reduction observed in clinical trials.

Indications (Investigational)

  • Obesity (Phase 2 and Phase 3 clinical trials)
  • Type 2 diabetes mellitus
  • Metabolic dysfunction–associated steatohepatitis (MASH) under investigation
  • Cardiometabolic risk modification (investigational)

Administration (Clinical Trial Reference)

Parameter Details
Route Subcutaneous
Frequency Once weekly
Injection Sites Abdomen, thigh, or upper arm (rotate sites)
Timing Administered on the same day each week

Pharmacokinetics (Clinical Trial Data)

Retatrutide demonstrates an approximate half-life of ~6 days, supporting once-weekly dosing. Peak plasma concentrations are typically observed within 24–72 hours after subcutaneous administration.

Steady-state concentrations are generally achieved after several weeks of weekly dosing. Metabolism occurs through proteolytic degradation into inactive peptide fragments.

Titration Schedule (Clinical Trial Reference)

The following dose-escalation schedule reflects strategies evaluated in clinical trials and is provided for literature reference only.

  • Weeks 1–4: 1–2 mg once weekly
  • Weeks 5–8: 4 mg once weekly
  • Weeks 9–12: 8 mg once weekly
  • Week 13+: 12 mg once weekly (highest studied dose in Phase 2)

Gradual dose escalation has been associated with improved gastrointestinal tolerability. More rapid escalation may increase the incidence of nausea, vomiting, and diarrhea.

Reconstitution & Concentration (Mathematical Standardization Model)

For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 1 mg. This allows consistent unit-to-milligram conversion across titration stages.

Parameter Value
Target Concentration 10 mg/mL
Unit Conversion 0.10 mL (10 units) = 1 mg
Example (12 mg vial) Reconstitute with 1.2 mL bacteriostatic water → 10 mg/mL
Stability 2–4 weeks refrigerated (varies by formulation and compounding standards)

Conversion Reference

  • 10 units = 1 mg
  • 20 units = 2 mg
  • 40 units = 4 mg
  • 80 units = 8 mg
  • 120 units = 12 mg

This section is provided strictly for arithmetic illustration and does not constitute dosing guidance. Commercial investigational formulations are supplied prefilled and are not reconstituted in this manner.

Safety & Contraindications (Summary)

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Known hypersensitivity to retatrutide or formulation components
  • Pregnancy or breastfeeding

Relative Cautions

  • History of pancreatitis
  • Severe gastrointestinal disease (e.g., gastroparesis)
  • Concomitant insulin or sulfonylurea therapy

Adverse Events

  • Nausea (dose-dependent)
  • Diarrhea
  • Vomiting
  • Constipation
  • Decreased appetite
  • Mild increases in heart rate

Serious Adverse Events

  • Pancreatitis (reported in incretin-based therapies)
  • Gallbladder disease
  • Severe gastrointestinal intolerance

Drug Interactions

  • Insulin or sulfonylureas may increase risk of hypoglycemia
  • Delayed gastric emptying may alter absorption of oral medications

Monitoring (Clinical Trial Based)

  • Fasting glucose and HbA1c (if used in diabetes populations)
  • Body weight and BMI
  • Heart rate
  • Liver enzymes (if underlying hepatic disease)
  • Symptoms suggestive of pancreatitis or gallbladder disease

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Disclaimer

Retatrutide is an investigational compound currently undergoing clinical evaluation. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.

Reference Sources